Compare McCormick & Company, Incorporated (MKC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Twist Bioscience Corp — how do they compare? McCormick & Company, Incorporated trades at $45.62 (market cap $12.39B), while Twist Bioscience Corp trades at $159 (market cap $10.08B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Twist Bioscience Corp for 27 Days on average.
| MKC | TWST | |
|---|---|---|
Market Cap | $12.39B | $10.08B |
Volume | 6,140,872 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $205.00 |
52-Week Low | $44.14 | $25.45 |
Typical Hold Time | 67 Days | 27 Days |
Enterprise Value | $17.07B | $10.01B |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.
The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
